Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial

Table 1 Demographic and endoscopic data of the two patient groups

Variable	mBCQT treatment (n = 68)	CT treatment (n = 68)	P value
Age (yr)	57.37 ± 11.31	60.09 ± 9.93	0.138
Gender (male:female)	40:28	32:36	0.169
Height (m)	1.64 ± 0.09	1.63 ± 0.08	0.420
Weight (kg)	64.61 ± 9.23	63.27 ± 9.69	0.409
BMI (kg/m2)	24.05 ± 2.88	23.87 ± 2.91	0.704
Smoking	12 (17.6)	14 (20.6)	0.663
Alcohol	18 (26.5)	18 (26.5)	0.999
Gastric and/or duodenal ulcer	27 (39.7)	19 (27.9)	0.147

The values are the mean ± SD, numbers only, or numbers with percentages. mBCQT: Modified bismuth-containing quadruple therapy; CT: Concomitant therapy; BMI: Body mass index.

Table 2 Eradication rates afforded by modified bismuth-containing quadruple therapy and concomitant therapy

	Eradication rate		P value
	mBCQT Treatment	CT Treatment
ITT analysis	88.2 (60/68)	79.4 (54/68)	0.162
PP analysis	98.4 (60/61)	93.1 (54/58)	0.199

mBCQT: Modified bismuth-containing quadruple therapy; CT: Concomitant therapy; ITT: Intention-to-treat; PP: Per-protocol. The values are percentages with numbers.

Table 3 Adverse events and compliance

	mBCQT treatment (n = 68)	CT treatment (n = 68)	P value
Diarrhea	1.5 (1)	13.2 (9)	0.009
Feces discoloration	5.9 (4)	0 (0)	0.119
Nausea	16.2 (11)	16.2 (11)	0.999
Taste disturbance	5.9 (4)	14.7 (10)	0.090
Miscellaneous	22.1 (15)	20.6 (14)	0.834
Total adverse events	33.8 (23)	51.5 (35)	0.037
Compliance1	85.3 (58)	82.4 (56)	0.641

¹≥ 90% of medications taken. The values are percentages with numbers. mBCQT: Modified bismuth-containing quadruple therapy; CT: Concomitant therapy.